3 Big Movers in Cancer Care -- Ariad Pharmaceuticals, Galena Biopharma, and Aratana Therapeutics

Ariad Pharmaceuticals (NASDAQ: ARIA), Galena Biopharma (NASDAQ: GALE), and Aratana Therapeutics (NASDAQ: PETX) have all served up a roller-coaster ride for shareholders in 2014.

Feb 2, 2014 at 4:45PM

One of the big movers in the health-care space in 2014 has been Ariad Pharmaceuticals (NASDAQ:ARIA). Shares in the biotechnology company that operates out of Cambridge, Mass., kicked off 2014 at $6.82, but on the back of a significant deal, shares hit $9.48 in the last week or so, before tailing off to close at $7.39 on Friday.

Certainly, 2014 has been a roller-coaster ride for Ariad shareholders!

The reason for the spike in the share price is news flow surrounding a leukemia treatment called Iclusig, with two pieces of positive news in the last couple of weeks.

The first was the announcement of the commercial availability of Iclusig for adult patients with chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. Ariad, therefore, began shipping Iclusig to Biologics, its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

This news comes shortly after the FDA had stopped sales of the drug because of apparent dangers from life-threatening blood clots. In response, Ariad added new labeling and updated the prescribing information, meaning the drug is now back on sale.

In addition, Ariad also announced that it has given an Australian specialty-drug maker the rights to sell Iclusig in Australia. The deal is set to last for seven years, after which time Ariad has the option to take over the sales function or extend the agreement (under the terms of the current deal, Specialised Therapeutics Australia will be responsible for obtaining marketing authorization and pricing approval).

Although no financial terms from the deal in Australia have been released, it looks to be an encouraging step forward for the business, with shares responding accordingly.

Of course, Ariad isn't the only health-care stock whose share price has been highly volatile in 2014 as a result of news flow surrounding cancer drugs. For instance, Galena Biopharma's (NASDAQ:GALE) share price rose from less than $5 on New Year's Eve to hit more than $7 in less than three weeks, with positive news flow surrounding its oncology treatments.

Galena announced that the first patient had been enrolled in a phase 2 trial for GALE-301, which is targeted at high-risk endometrial and ovarian cancer patients. It also acquired Mills Pharmaceuticals, a biopharmaceutical company that specializes in the development and commercialization of targeted oncology treatments. Furthermore, Galena also announced a strategic partnership with Dr. Reddy's in India, which is focused on a commercialization partnership on NeuVax.

Clearly, cancer is a space where there is great demand for drug development. However, this is not just the case for human oncology patients, with shares in Aratana Therapeutics (NASDAQ:PETX) being a big mover in the last week because of encouraging progress made with a drug designed to treat T-cell lymphoma in dogs.

The drug was granted conditional approval by the U.S. Department of Agriculture to market the drug, although Aratana will run additional studies to further support its safety and effectiveness.

As a result, shares climbed from $18.76 at the start of the week to close at $21.51 on Friday -- a 15% gain.

So, with Ariad, Galena, and Aratana serving up a roller-coaster ride to the start of 2014, it has certainly been an interesting way to kick off the New Year for investors in those companies. Who would bet that the rest of 2014 will be any different?

The Motley Fool's top stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers